These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21967521)

  • 41. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
    Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
    Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing splice-switching oligomer sequences using 2'-O-methyl phosphorothioate chemistry.
    Adkin C; Fletcher S; Wilton SD
    Methods Mol Biol; 2012; 867():169-88. PubMed ID: 22454061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
    Mitrpant C; Fletcher S; Iversen PL; Wilton SD
    J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Splicing analysis disclosed a determinant single nucleotide for exon skipping caused by a novel intraexonic four-nucleotide deletion in the dystrophin gene.
    Tran VK; Takeshima Y; Zhang Z; Yagi M; Nishiyama A; Habara Y; Matsuo M
    J Med Genet; 2006 Dec; 43(12):924-30. PubMed ID: 16738009
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
    Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
    Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Categorization of 77 dystrophin exons into 5 groups by a decision tree using indexes of splicing regulatory factors as decision markers.
    Malueka RG; Takaoka Y; Yagi M; Awano H; Lee T; Dwianingsih EK; Nishida A; Takeshima Y; Matsuo M
    BMC Genet; 2012 Mar; 13():23. PubMed ID: 22462762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
    Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
    Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.
    Hammond SM; Wood MJ
    Curr Opin Mol Ther; 2010 Aug; 12(4):478-86. PubMed ID: 20677099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle.
    Gebski BL; Mann CJ; Fletcher S; Wilton SD
    Hum Mol Genet; 2003 Aug; 12(15):1801-11. PubMed ID: 12874101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe.
    Matsuo M; Masumura T; Nishio H; Nakajima T; Kitoh Y; Takumi T; Koga J; Nakamura H
    J Clin Invest; 1991 Jun; 87(6):2127-31. PubMed ID: 2040695
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modification of pre-mRNA processing: application to dystrophin expression.
    Wilton SD; Fletcher S
    Curr Opin Mol Ther; 2006 Apr; 8(2):130-5. PubMed ID: 16610765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Endogenous Multiple Exon Skipping and Back-Splicing at the DMD Mutation Hotspot.
    Suzuki H; Aoki Y; Kameyama T; Saito T; Masuda S; Tanihata J; Nagata T; Mayeda A; Takeda S; Tsukahara T
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Local dystrophin restoration with antisense oligonucleotide PRO051.
    van Deutekom JC; Janson AA; Ginjaar IB; Frankhuizen WS; Aartsma-Rus A; Bremmer-Bout M; den Dunnen JT; Koop K; van der Kooi AJ; Goemans NM; de Kimpe SJ; Ekhart PF; Venneker EH; Platenburg GJ; Verschuuren JJ; van Ommen GJ
    N Engl J Med; 2007 Dec; 357(26):2677-86. PubMed ID: 18160687
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative Evaluation of Exon Skipping in Immortalized Muscle Cells In Vitro.
    Lim KRQ; Yokota T
    Methods Mol Biol; 2018; 1828():127-139. PubMed ID: 30171538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro splicing analysis showed that availability of a cryptic splice site is not a determinant for alternative splicing patterns caused by +1G-->A mutations in introns of the dystrophin gene.
    Habara Y; Takeshima Y; Awano H; Okizuka Y; Zhang Z; Saiki K; Yagi M; Matsuo M
    J Med Genet; 2009 Aug; 46(8):542-7. PubMed ID: 19001018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene.
    Nishida A; Kataoka N; Takeshima Y; Yagi M; Awano H; Ota M; Itoh K; Hagiwara M; Matsuo M
    Nat Commun; 2011; 2():308. PubMed ID: 21556062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.